DYN
Dyne Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$16.69Close
$2.8BMarket cap
$14.25 – $26.7852-week range
Nov 4, 2026Next report
Highlights
Strengths
- Tight base near its pivot pullbacks 45% → 18%; 3.6% below its $17.31 pivot
- Volume drying up last 10 days 25% under the 50-day average
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 14 · weaker than 86% of stocks over 12 months
- Far from its high 38% below its 52-week high
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
38%
1wk
up 6.9%
price change
1mo
up 3.6%
price change
12-month return
down 29%
market up 11% ·
its own down 40%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.8×
price / book
Earnings yield
down 23.3%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
0%
return on equity
Free cash margin
—
-$405.1M FCF
D/E
0.15
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.5%
$0.91 a day · 2×ATR $14.87
RS
14 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.69
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Contractions
2
45% → 18%
Pivot
$17.31
3.6% below
Volume dry-up
0.7×
10 vs 50 sessions
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 61.2% over the year, from 102m to 165m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Jul 29, 2026
Last shock
Sep 8, 2026-16% in one session6.9× volumeno filing matched-18% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$58.6M | -$150.0M | -$171.0M | -$242.2M | -$343.9M | -$468.2M |
| Net income | -$59.4M | -$149.3M | -$168 | -$236 | -$317 | -$446 |
| Free cash flow | -$47.7M | -$123.2M | -$156.7M | -$188.9M | -$294.7M | -$405.1M |
| Cash | $300.9M | $200.8M | $172.1M | $121.6M | $435.4M | $893.4M |
| Long-term debt | — | — | — | — | $0 | $148.9M |
| Shareholders' equity | $342.4M | $368.2M | $252.4M | $91.3M | $629.8M | $972.1M |
| Shares outstanding | 45.08m | 51.57m | 55.64m | 61.47m | 102.32m | 164.95m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 29, 2026 | Quarterly ↗ | Jun 30, 2026 | 29d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Jul 28, 2025 | Quarterly ↗ | Jun 30, 2025 | 28d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Mar 5, 2024 | Annual ↗ | Dec 31, 2023 | 65d |
| Oct 30, 2023 | Quarterly ↗ | Sep 30, 2023 | 30d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 29, 2026 | Regulation FD · Other events ↗ |
| Jul 29, 2026 | Results ↗ |
| Jul 22, 2026 | Material agreement · Other events ↗ |
| Jul 20, 2026 | Other events ↗ |
| Jun 22, 2026 | Director or officer change ↗ |
| Jun 17, 2026 | Material agreement · New obligation ↗ |
| Jun 8, 2026 | Shareholder vote ↗ |
| Jun 3, 2026 | Regulation FD · Other events ↗ |
| May 11, 2026 | Results ↗ |
| Mar 2, 2026 | Results ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Dec 23, 2025 | Director or officer change ↗ |